7-Ketoabiraterone Acetate

This compound has been investigated in preclinical and early clinical studies for its potential in treating prostate cancer, particularly in cases where resistance to conventional hormone therapy has developed.

Research on 7-Ketoabiraterone acetate is ongoing to evaluate its safety and effectiveness in prostate cancer treatment. It may offer advantages over abiraterone acetate due to its potentially improved selectivity and potency in inhibiting CYP17A1.

As with any investigational drug, the development and approval process for 7-ketoabiraterone will depend on the results of clinical trials, regulatory considerations, and further research to establish its safety and efficacy.